Connect with us

Oxford News

Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment

Published

on


The acquisition is expected to help accelerate the development of a new type of targeted treatment for leukaemia, with the potential to improve outcomes for patients. It is also hoped that this treatment could be expanded to other cancers.

The scientific foundations of the programmes were built on discoveries made by Oxford researchers including Oleg Fedorov, Cassandra Adams, Gilian Farnie, Kilian Huber and Paul Brennan in the Centre for Medicines Discovery; Christian Siebold in the Division of Structural Biology (STRUBI) at the Nuffield Department of Medicine; and Thomas Milne and Nicholas Crump in the MRC Weatherall Institute of Molecular Medicine at the Radcliffe Department of Medicine.

The research was further strengthened by complementary expertise across the University, including the Dunn School of Pathology, notably the groups of Professor Monika Gullerova and Professor Ivan Ahel. The work was also supported by the Structural Genomics Consortium (SGC), a global public-private partnership focused on open science.

The move from academic discovery to early-stage drug development began within Lab282, a £13 million partnership between the University of Oxford, the drug discovery company Evotec and Oxford Sciences Enterprises (OSE), and Bristol Myers-Squibb. Lab282 was created to bridge the gap between research and drug discovery, supporting promising projects as they move towards commercialisation.

Commenting on the role of Lab282 as an incubator, Professor Paul Brennan of the Centre for Medicines Discovery said: ‘We set out to create a model that could reduce risk early by combining strong biology with high-quality chemistry, while keeping future development in mind. Lab282 was designed to help move promising academic science into a setting where it could be developed further with industry partners. Amgen’s investment in the science demonstrates how the Lab282 model can progress promising academic research to a stage attractive to global pharmaceutical partners.’

This translational work laid the foundations for the creation of a new company to take the programme forward. Dark Blue Therapeutics an Oxford spinout, was founded to advance this research towards new medicines – focused on developing first-in-class small-molecule therapies that target cancer-driving proteins previously considered difficult to treat.

Professor Thomas Milne explains: ‘The company is developing a novel approach to treating leukaemia by targeting proteins that drive cancer growth in aggressive blood cancers, including acute myeloid leukaemia (AML). Our research showed that this approach can inhibit the growth of leukaemia cells while largely sparing healthy cells, raising the prospect of a more effective and better-tolerated treatment.’

The lead drug candidate developed by Dark Blue Therapeutics is now in preclinical development, with studies under way to enable testing in patients. Amgen’s acquisition of the company will provide the resources and expertise needed to take the programme into clinical trials.

John Pollard, the Chief Scientific Officer at Dark Blue and a visiting Professor of Drug Discovery at the University reflected: ‘The discovery of this exciting new class of drugs demonstrates the enormous potential in the Oxford ecosystem that can be realised when ground breaking disease insights from the Universities’ world leading scientists are leveraged by expert industrial drug hunters in a truly collaborative manner.’

The Amgen deal reflects the strength of Oxford’s wider innovation ecosystem, combining world-leading science, incubator support, spin-out expertise, and industry partnership. Together, these elements create a framework through which promising biomedical research can be advanced from discovery to commercial development, supporting the progression of future therapeutic programmes emerging from Oxford.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Oxford News

New date set for Tommy Robinson appearance in Oxford

Published

on


The controversial figure, whose real name is Stephen Yaxley-Lennon, was due to speak at the Oxford Union on Thursday, May 28 before it was postponed over security concerns.

Yaxley-Lennon has been jailed multiple times for a variety of offences with his significant recent imprisonment in October 2024 for contempt of court.

And his planned visit had sparked furious backlash, with politicians in Oxfordshire saying he is “not welcome” to the city.

Tommy Robinson. (Image: PA)

However, a source at the historic debating society told this newspaper that Yaxley-Lennon is now due to appear for his debate on Islam on Wednesday, June 17.

The source added that this was the day before the Union’s Palestine debate on June 18.

“The concern is that the Union intends to announce the debate only shortly before it happens, apparently to minimise public backlash and make it harder for students, local councillors, community groups, or the police to respond in time,” the source added.

“There is also concern that the timing is designed to avoid internal accountability: under Union rules, the final date to file a no-confidence motion against president Arwa Elrayyes is understood to be 5 June.

“Announcing the event after that date would effectively prevent members from using that route against her before the end of term.”

The Oxford Union has not responded to requests for comment around the new date.

It’s been reported that Thames Valley Police quoted the Oxford Union security and policing costs between £50,000 and £80,000 to safely host the debate.

It’s also been reported that the Oxford Union is facing a “financial crisis” with donations drying up after the Charlie Kirk scandal in which the former president-elect appeared to make light of the US commentator’s assassination.

Thames Valley Police was asked whether it would be attending the debate and expected protest outside.

A spokeswoman said: “We work closely with partners through established safety advisory structures to ensure local events run safely and smoothly, while minimising disruption to our communities.”

In a statement announcing the postponement, the Oxford Union said: “The Fifth Week debate has been postponed from 28 May to later this term to allow time for planning of the event.

“We are grateful to our local partners and stakeholders for their continued support and engagement.

“We expect to confirm the new date shortly, following discussions with our speakers.”

Oxford East MP Anneliese Dodds also expressed concern at Yaxley-Lennon appearing in Oxford.

She said: “The hatred promoted by Stephen Yaxley-Lennon, also known as Tommy Robinson, has no place in our great city.”





Source link

Continue Reading

Oxford News

Oxford stalker to appear again at magistrates’ court

Published

on



Zac Sanger-Reynolds, of North Hinksey Lane in Oxford, previously plead guilty to stalking at High Wycombe Magistrates’ Court on Friday, April 28.

He will appear at the Buckinghamshire court on Thursday, June 4 for an application to vary a restraining order.

READ MORE: Documents show Oxfordshire footbridge has been sub-standard for over decade

Sanger-Reynolds was handed the order in April after a mother-of-two spoke to the Oxford Mail about his ‘obsession’ after she became uninterested in him after two dates.

He was told to complete 100 hours of un-paid, supervised work within 12 months and undertake 26 days of rehabilitation.

He was also ordered to pay £199, including £114 for the victim surcharge and £85 to the Crown Prosecution Service.





Source link

Continue Reading

Oxford News

Controversial Oxfordshire homes approved despite concerns

Published

on


Construction company Taylor Wimpey was granted the development on appeal in 2017 for up to 95 homes at Thames Farm, off Reading Road in Lower Shiplake.

It has since reduced this to 84 to provide adequate drainage because “the land is unstable and vulnerable to sinkholes”.

Taylor Wimpey said the new drainage plans will ensure there are no off-site impacts relating to surface water and this will include a basin on the western part of the site.

Members of the Thames Farm Action Group, which represents Shiplake residents, have concerns about the environmental impact of the scheme, which they say has no precedent in the UK.

The ground would have to be injected with grout and concrete to keep stable despite it sitting on top of an aquifer that supplies water to nearby towns.

READ MORE: Police action continues over dual carriageway after dangerous races

Freddie van MierloFreddie van Mierlo has consistently objected to the plans (Image: Contributed)

In July 2025, the planning committee of South Oxfordshire District Council voted to refuse the ground-stabilisation application despite a recommendation for approval.

Councillors cited concerns about possible impacts on the aquifer and public water supply.

The formal refusal notice stated the application “failed to demonstrate that the proposed engineering operations would not pose an unacceptable risk to the aquifer and nearby public water abstraction points”.

But now the plans have been given the go ahead by a separate planning inspector.

Despite objections from the district council the project appears to have been given the go ahead.

Freddie Van Mierlo, MP for Henley and Thame, said: “I will be working with The Thames Farm Action Group, Henley Town Council, Shiplake Parish Council and Harpsden Councils to ensure their voices are heard.”

The new report states there is a risk, but it’s “an acceptable level of risk” for the area.





Source link

Continue Reading

Trending